CLINICAL ROLE -
The ASCO Annual Meeting is hosted by the American Society of Clinical Oncology. The meeting offers presentations on the latest research in oncology care.
Advocacy, Education of Individuals With Myeloproliferative Neoplasms Are Important to Support Patient Engagement, Outcomes
Pharmacists also have the resources to help advocate for better care for patients.
Natural Killer Cells: A Potential New Frontier in the Fight Against Cancer?
Early safety studies of NK-cell infusion have demonstrated the potential of NK-cell infusion, showing it may be the next revolution in cancer treatment.
A Prevention Strategy for Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast Cancer May Be in Sight
There are currently no effective treatments for CIPN prevention.
PROSPECT Trial Shows De-escalation of Rectal Cancer Treatment Can Achieve Same High Cure Rate With Less Toxicity
These data support a paradigm shift in the treatment of locally advanced rectal cancer.
Second-Generation Combination Treatment Shows Long-Term Efficacy Against Advanced Kidney Cancer
With approximately 2 years of additional follow-up, lenvatinib plus pembrolizumab maintained robust effectiveness for nearly every patient.
Nivolumab-AVD Is Poised to Be New Standard of Care for Hodgkin Lymphoma in Adult and Pediatric Patients
The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.
Overall Survival Results Reinforce Osimertinib as Standard of Care for EGFRm Stage IB-IIIA NSCLC
Updated phase 3 trial data provide practice-changing findings.
Notable ASCO Trial Data Have the Potential to Transform Oncology Pharmacy Practice
These study results may inform clinical practice strategies this year and beyond.
Golidocitinib May Be Effective for The Most Difficult-To-Treat Subtypes of Peripheral T-cell Lymphoma
Approximately 50% of patients with refractory or relapsed disease achieved complete response following treatment with the Janus kinase 1 (JAK1) inhibitor.
Luspatercept-aamt Shows Efficacy Treating Anemia Due to Myelodysplastic Syndromes
Trial results demonstrated that 58.5% of individuals receiving luspatercept-aamt (Reblozyl; Bristol Myers Squibb) achieved the primary endpoint of red blood cell transfusion independence of at least 12 weeks.
Genomic Testing is Good But Not Great, According to Expert
Earlier in June, Govindan led an educational session about genomic testing at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Expert: Mirvetuximab Soravtansine-Gynx Does Not Use Up the "Precious Reserves” of Patients with Ovarian Cancer
The folate alpha receptor (FRα) does have a toxicity profile, but unlike other chemotherapies, it does not severely compromise bone marrow and may improve ability to receive more therapies.
The Enhancing Oncology Model Promotes Novel Therapies, May Reduce Cost of Care
Expert provides numerous resources to learn more about the Centers for Medicare & Medicaid Services Enhancing Oncology Model.
New Data From CodeBreaK Clinical Trial Demonstrate Efficacy of Sotorasib for NSCLC, Colorectal Cancer
Additionally, data from the SCARLET trial presented at ASCO 2023 indicate the safety and efficacy of sotorasib in combination with platinum-based chemotherapy treating non¬–small cell lung cancer.
Investigational Individualized Neoantigen Therapy, Pembrolizumab Improve Distant Metastasis-Free Survival in Melanoma
The combination also reduced the risk of developing distant metastasis or death by 65% in patients with high-risk stage 3/4 melanoma.
Trastuzumab Deruxtecan Demonstrates Responses Across Advanced Solid Tumors With HER2 Expression
Trial results support 5.4 mg/kg of trastuzumab deruxtecan as the optimal dose in individuals with HER2+ metastatic colorectal cancer.
Expert: KEYNOTE-716 Could be a "Game-Changer" for Patients with Stage 2 Melanoma At High Risk of Recurrence
Until this study, adjuvant immunotherapy was standard of care for stage 3B melanoma but not stage 2, which has relatively similar survival rates and risk of recurrence.
Liso-Cel CAR T-Cell Therapy May Significantly Reduce Relapse, Recurrence of Lymphoma
Asking patients to “give us a month of [their] life” for autologous chimeric antigen receptor therapy may reduce relapse or recurrence for 4 years or more, according to expert.
Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple Myeloma
Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells.
Nivolumab-AVD Poised to be New Standard of Care for Hodgkin Lymphoma in Both Adults, Pediatric Patients
Long-term Data Show Efficacy of Amivantamab-vmjw Combination for Patients With Mutated Advanced Non-Small Cell Lung Cancer
In data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer.
Overall Survival of Patients With Metastatic NSCLC Sustained Up to 4 Years With Opdivo, Yervoy Combination
Nivolumab plus ipilimumab combination improved overall survival, with 21% of individuals with metastatic non–small cell lung cancer treated with the combination and 2 cycles of chemotherapy alive compared to 16% with chemotherapy alone.
Durvalumab, Olaparib Combination Improves Progression-Free Survival in Patients With Advanced Ovarian Cancer
Positive findings in patients with advanced high-grade epithelial ovarian cancer were presented during an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting.
Targeting Folate Receptor Alpha Provides Therapeutic Benefits for Platinum-Resistant Ovarian Cancer
Expert suggests that mirvetuximab soravtansine-gynx, which received accelerated approval in the platinum-resistant ovarian cancer setting in 2022, is the most promising agent in more than a decade that targets folate receptor alpha.
Vorasidenib Significantly Improves PFS in Grade 2 Gliomas With Manageable Safety Profile
Current standard of care gives 2 poor options to patients, neither of which cure grade 2 gliomas.
Approximately 25% of Eligible Survivors of Breast, Cervical Cancers Did Not Receive Follow-Up Instructions for Post-Treatment Screening
When physicians followed up, rates of screening improved for breast and cervical cancer by 50% and 250%, respectively, among eligible cancer survivors.
Overall Survival Results Reinforce Osimertinib is Now Standard of Care for EGFRm Stage IB–IIIA NSCLC
Updated overall survival and safety profile data from the global phase 3 ADAURA trial provide practice-changing findings with adjuvant osimertinib (Tagrisso; AstraZeneca) in patients with resected EGFR-mutated stage IB–IIIA NSCLC.
With Perioperative Pembrolizumab, Event-Free Survival for Early-Stage Lung Cancer Was 62% at the Interim Analysis of Phase 3 KEYNOTE-671
Expert said these striking results, coupled with benefits across all subgroups and potential overall survival, suggests efficacy for adults with early-stage non-small cell lung cancer.
Addition of Pembrolizumab to Chemotherapy Can Significantly Improve Survival Outcomes in Patients with Cervical Cancer
Expert discusses the long wait for an effective therapeutic option for persistent, recurrent, or metastatic cervical cancer and the potential widespread benefits of antibody drug conjugates like pembrolizumab.
New FGFR Inhibition Therapies Show Promise in Intrahepatic Cholangiocarcinoma
Biliary tract cancers have become the model for precision oncology because of its complex molecular landscape.
2 Clarke Drive Cranbury, NJ 08512